

Certificate of Analysis

IGF-1R, activated

(Recombinant enzyme expressed in Sf21 insect cells)

Item # 14-802, 14-802-K, 14-802M

Parent Lot # D7MN033N

The data presented in this document apply to the parent lot shown above and to all pack sizes derived from subsequent vialling runs of this parent lot. An alphabetical suffix after the parent lot number is used to denote each vialling run.

Product Description: N-terminal 6His-tagged, recombinant, human IGF-1R amino acids 959–end, expressed by baculovirus in Sf21 insect cells. Purified using Ni²⁺/NTA agarose. Autoactivated on column by incubating with Mg/ATP, excess ATP and MgAc removed by multiple column wash steps.

Purity 88.3% by SDS-PAGE and Coomassie blue staining. MW = 48kDa.

Specific Activity (Parent lot# D7MN033N): 3661U/mg, where one unit of IGF-1R activity is defined as 1nmol phosphate incorporated into 500µM IGFtide (KKKSPGEYVNIEFG) per minute at 30°C with a final ATP concentration of 100µM.

Formulation: 1.984mg/ml of enzyme in 50mM Tris/HCl pH7.5, 150mM NaCl, 0.1mM EGTA, 0.03% Brij-35, 270mM sucrose, 1mM benzamidine, 0.2mM PMSF, 0.1% 2-mercaptoethanol, 5mM β-glycerophosphate, 1mM Na₃VO₄. Frozen solution.


Storage and Stability: On receipt of material store at -70°C. Unopened reagent is stable for a minimum of 1 year from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap.

Handling Recommendations: Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled microcentrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70°C.

**FOR IN VITRO RESEARCH USE ONLY
NOT FOR USE IN HUMANS OR ANIMALS**


Quality Control Testing

Kinase Assay: 0.4–5.0ng of this lot of enzyme phosphorylated 500µM IGFtide (KKKSPGEYVNIEFG) in the assay described on page two. Assay background was subtracted from the actual counts to yield the results shown below.



MS Tryptic Fingerprint: Confirmed identity as IGF-1R with the translated sequence listed on page three.

SDS-PAGE and Coomassie Stain: Purity was assessed by SDS-PAGE and Coomassie blue staining using 3µg of IGF-1R, activated.



Certificate of Analysis

Kinase Assay Protocol

Stock Solutions:

- 1. 5 x Reaction Buffer:** 40mM MOPS/NaOH pH7.0, 1mM EDTA.
- 2. Na₃VO₄:** Use at a final assay concentration of 1mM. Prepare a 100mM stock and add 0.25µl of stock per assay point.
- 3. Na-β-glycerophosphate:** Use at a final assay concentration of 5mM. Prepare a 1M stock and add 0.125µl of stock per assay point.
- 4. IGFtide (KKKSPGEYVNIEFG):** Use at a final assay concentration of 500µM. Prepare a 5mM stock and add 2.5µl of stock per assay point.
- 5. IGF-1R, activated:** Dilute with 20mM MOPS/NaOH pH7.0, 1mM EDTA, 0.01% Brij-35, 5% glycerol, 0.1% 2-mercaptoethanol, 1mg/ml BSA. Use 0.4–5.0ng per assay point.
- 6. [γ-³³P]ATP:** 2.5 x magnesium acetate/[γ-³³P]ATP cocktail: 25mM MgAc and 0.25mM ATP to which is added [γ-³³P]ATP (specific activity approximately 500 - 800cpm/pmol as required.)

Assay Procedure (96 well plate format):

1. Add 5µl of 5 x reaction buffer per assay to wells
2. Add 2.5µl of **IGFtide (KKKSPGEYVNIEFG)**.
3. Add **2.5µl (0.4–5.0ng) IGF-1R, activated**.
4. Add 4.625µl of dH₂O.
5. Add 0.25µl Na₃VO₄
6. Add 0.125µl Na-β-glycerophosphate.
7. Add 10µl of diluted [γ-³³P]ATP mixture.
8. Incubate for 10 minutes at 30°C.
9. Stop the reaction by adding 5µl of 3% phosphoric acid.
10. Transfer a 10µl aliquot onto the appropriate area of a **P30 Filtermat**.
11. Wash the filtermat three times for 5 minutes with 75mM phosphoric acid.
12. Wash the filtermat once for 2 minutes with methanol.
13. Transfer the filtermat to a sealable plastic bag and add 4ml of scintillation cocktail.
14. Read in a scintillation counter. Compare cpm of enzyme samples with cpm of control samples that contain all assay components plus 1µl of 30% phosphoric acid.

Certificate of Analysis

IGF-1R Sequence Information

<u>Protein</u>	human IGF-1R
<u>Tags</u>	N-terminal 6His
<u>Native sequence</u>	H16 of the recombinant protein is equivalent to H959 of human IGF-1R
<u>Accession number</u>	GenBank X04434

Recombinant IGF-1R amino acid sequence:

```

1 MAHHHHHHEN LYFQGHRKRN NSRLGNGVLY ASVNPEYFSA ADVYVPDEWE VAREKITMSR
61 ELGQGSFGMV YEGVAKGVVK DEPETRVAIK TVNEAASMRE RIEFLNEASV MKEFNCHHVV
121 RLLGVVSQOQ PTLVIMELMT RGDLSKYLRS LRPEMENNVP LAPPSLSKMI QMAGEIADGM
181 AYLNANKFVH RDLAARNCMV AEDFTVKIGD FGMTRDIYET DYYRKGGKGL LPVRWMSPE
241 LKDGVFTTYD DVWSFGVVLW EIATLAEQPY QGLSNEQVLR FVMEGGLLDK PDNCPDMLFE
301 LMRMCWQYNP KMRPSFLEII SSIKEEMEPG FREVSFYFSE ENKLPEPEEL DLEPENMESV
361 PLDPSASSSS LPLPDRHSGH KAENGP GPGV LVLRSFDER QPYAHMNGGR KNERALPLPQ
421 SSTC

```

Recombinant IGF-1R nucleotide sequence:

```

1 atggcgcatac accatcacca tcatgaaaac ctgtattttc agggccatag aaagagaaat
61 aacagcagggc tggggaatgg agtgctgtat gcctctgtga acccgagta cttcagcgct
121 gctgatgtgt acgttcctga tgagtgggag gtggctcggg agaagatcac catgagccgg
181 gaacttgggc aggggtcgtt tgggatggtc tatgaaggag ttgccaaggg tgtggtgaaa
241 gatgaacctg aaaccagagt ggccattaaa acagtgaacg aggccgcaag catgcggtgag
301 aggattgagt ttctcaacga agcttctgtg atgaaggagt tcaattgtca ccatgtggtg
361 cgattgctgg gtgtggtgtc ccaaggccag ccaacactgg tcatcatgga actgatgaca
421 cggggcgatc tcaaaagtta tctccggctc ctgaggccag aaatggagaa taatccagtc
481 ctagcacctc caagcctgag caagatgatt cagatggccg gagagattgc agacggcatg
541 gcataacctca acgccaataa gttcgtccac agagacctg ctgcccggaa ttgatggta
601 gccgaagatt tcacagtcaa aatcggagat ttgggtatga cgcgagata ctatgagaca
661 gactattacc ggaaggagg gaaaggctg ctgcccgtgc gctggatgtc tctctgagtc
721 ctcaaggatg gactctcac caactactcg gacgtctggt ccttcggggt cgtcctctgg
781 gagatcgcca cactggccga gcagccctac cagggttgtt ccaacgagca agtccttcgc
841 ttcgtcatgg agggcggcct tctggacaag ccagacaact gtcctgacat gctgtttgaa
901 ctgatgcgca tgtgctggca gtataacccc aagatgaggc cttccttctt ggagatcatc
961 agcagcatca aagaggagat ggagcctggc ttccgggagg tctccttcta ctacagcgag
1021 gagaacaagc tgcccagacc ggaggagctg gacctggagc cagagaacat ggagagcgtc
1081 cccctggacc cctcggcctc ctctcctcct ctgccaactgc ccgacagaca ctcaggacac
1141 aaggccgaga acggcccgg cctgggggtg ctggctctcc cgcgagcgtt cgacgagaga
1201 cagccttacg cccacatgaa cgggggcccgc aagaacgagc gggccttggc gctgccccag
1261 tcttcgacct gctga

```

Reviewed and approved by site quality representative.

Unless otherwise stated in our catalogue or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

© 2014 Eurofins Pharma Discovery Services UK Limited is an independent member of Eurofins Discovery Services.